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RESEARCH ARTICLE
Bone Marrow Transplantation Stimulates
Neural Repair in Friedreich’s Ataxia Mice
Kevin C. Kemp, MSc, PhD,1 Kelly Hares, BSc, PhD,1 Juliana Redondo, BSc, PhD,1
Amelia J. Cook, BSc,1 Harry R. Haynes, MBChB, PhD,2
Bronwen R. Burton, BSc, PhD,3 Mark A. Pook, BSc, PhD,4
Claire M. Rice, FRCP, PhD,1 Neil J. Scolding, FRCP, PhD,1 and
Alastair Wilkins, FRCP, PhD1
Objective: Friedreich’s ataxia is an incurable inherited neurological disease caused by frataxin deficiency. Here, we
report the neuroreparative effects of myeloablative allogeneic bone marrow transplantation in a humanized murine
model of the disease.
Methods: Mice received a transplant of fluorescently tagged sex-mismatched bone marrow cells expressing wild-
type frataxin and were assessed at monthly intervals using a range of behavioral motor performance tests. At 6
months post-transplant, mice were euthanized for protein and histological analysis. In an attempt to augment num-
bers of bone marrow–derived cells integrating within the nervous system and improve therapeutic efficacy, a sub-
group of transplanted mice also received monthly subcutaneous infusions of the cytokines granulocyte-colony
stimulating factor and stem cell factor.
Results: Transplantation caused improvements in several indicators of motor coordination and locomotor activity.
Elevations in frataxin levels and antioxidant defenses were detected. Abrogation of disease pathology throughout
the nervous system was apparent, together with extensive integration of bone marrow–derived cells in areas of ner-
vous tissue injury that contributed genetic material to mature neurons, satellite-like cells, and myelinating Schwann
cells by processes including cell fusion. Elevations in circulating bone marrow–derived cell numbers were detected
after cytokine administration and were associated with increased frequencies of Purkinje cell fusion and bone mar-
row–derived dorsal root ganglion satellite-like cells. Further improvements in motor coordination and activity were
evident.
Interpretation: Our data provide proof of concept of gene replacement therapy, via allogeneic bone marrow trans-
plantation, that reverses neurological features of Friedreich’s ataxia with the potential for rapid clinical translation.
ANN NEUROL 2018;83:779–793
Friedreich’s ataxia (FA) is an autosomal recessive inher-ited ataxia caused, in >95% of cases, by a homozy-
gous GAA.TTC trinucleotide repeat expansion within
intron 1 of the FXN gene.1 This triplet expansion results
in transcriptional repression of frataxin,2 a small mito-
chondrial protein involved in iron–sulfur cluster biosyn-
thesis. Typically, patients with the condition experience
insidious accumulation of neurological disability charac-
terized pathologically by lesions in the dorsal root ganglia
(DRG), sensory peripheral nerves, spinal cord, and cere-
bellar dentate nucleus.3,4
Neuronal atrophy and dysfunctional glia are both
thought to contribute to neuropathology in FA.3,5–7
Despite advances in understanding of the disease, current
therapeutics show little ability to protect nervous tissue
and no capacity to promote repair. Adult stem cell popu-
lations, notably those that reside within the bone marrow
(BM), have been shown both to provide neurotrophic
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support and to contribute to neuronal/glial cell types in
the brain through processes likely involving cellular
fusion.8–13 The observation that BM cells can migrate
and integrate within the nervous system, and persist
apparently for decades,8,9 may offer a biological mecha-
nism that can be exploited therapeutically.12,13 Utilizing
allogenic BM transplantation (BMT) as a mode of gene
therapy, to provide a source of "genetically normal"
donor cells to access affected tissue and support endoge-
nous cells of the central and peripheral nervous system,
may afford significant therapeutic potential,14,15 particu-
larly in a multi-system disease such as FA.
We have recently described the neuroprotective
properties of both granulocyte-colony stimulating factor
(G-CSF) and stem cell factor (SCF) in a murine model
of FA,16 two agents used in clinical practice to mobilize
BM stem cells prior to a peripheral blood (PB) stem cell
harvest.17,18 In both healthy animals and animals with
central nervous system (CNS) injury, the numbers of
BM-derived cells detectable in the brain are increased fol-
lowing treatment with G-CSF and SCF.19,20 This implies
that migration of BM-derived cells into the nervous sys-
tem has potential for therapeutic manipulation, and in
addition to their neuroprotective effects in FA,16 G-CSF
and SCF may also aid the delivery of BM cells to sites of
injury in the disease, stimulating neural repair.
Here, we explore whether myeloablative allogeneic
BMT of cells expressing the wild-type Fxn gene can be
harnessed as a potential neuroreparative gene therapy for
FA; and secondly, to extend our previous studies, whether
subsequent administration of G-CSF and SCF can
enhance BM-derived cell integration within the diseased
nervous system and improve therapeutic efficacy.
Materials and Methods
Experimental Design
Both wild-type control mice and YG8R mice received a mye-
loablative allogeneic BMT to produce transplanted wild-type
controls (BMT control) and transplanted YG8R mice (BMT
YG8R). A subgroup of BMT YG8R mice also received monthly
infusions of G-CSF/SCF (BMT YG8R G-CSF/SCF). Experi-
mental protocols are described in Figure 1A and B. Sample
sizes were based on our previous reports using the YG8R
model.16
Animals
All animal experiments were performed in accordance with the
UK Animals (Scientific Procedures) Act 1986 and approved by
the University of Bristol Animal Welfare and Ethical Review
Body. Female Fxntm1Mkn Tg(FXN)YG8Pook/J (YG8R) trans-
genic mice, which carry a human genomic FXN transgene (on a
murine frataxin null background) containing expanded GAA
repeats of 82 to 190 units within intron 1 of FXN, were used.
(Sex differences in disease trajectory are reported in YG8R
mice; female YG8R mice show a stronger behavioural pheno-
type and reduced frataxin protein in the brain, when compared
to male YG8R mice, that more closely resembles human dis-
ease.21) Both ataxic (strain # Fxntm1Mkn Tg[FXN]YG8Pook/J,
stock # 008398) and transgenic mice ubiquitously expressing
enhanced green fluorescent protein (EGFP; strain # C57BL/6-
Tg[CAG-EGFP]131Osb/LeySopJ, stock # 006567) were pur-
chased from The Jackson Laboratory (Bar Harbor, ME). Con-
trol C57BL/6 VAF/Elite mice were provided by Charles River
UK (Margate, UK). Genotyping was performed by The Jackson
Laboratory to confirm the genetic background of all YG8R
mice, and upon arrival, mice were randomly assigned to a treat-
ment group. Mice were housed in a pathogen-free facility, with
free access to sterile food and water.
BMT: Generation of EGFP-Expressing BM
Chimeric Mice
Donor BM cells were harvested, under sterile conditions, from
10- to 12-week-old male C57BL/6 EGFP-expressing transgenic
mice.22 Twelve-week-old female recipient mice (control and
YG8R mice) were lethally irradiated, with a single dose of
1,000rad from a Cesium-137 source, 6 hours prior to receiving
13 107 unfractionated EGFP-expressing donor BM cells by tail
vein injection. Founder mice of both parent lines used to gener-
ate the YG8R mouse had been back-crossed to C57BL/6 for 5
generations23,24; thus, no immunosuppression was provided
post-transplant.
Wild-type BM donor mice were male, and recipients
(control and YG8R mice) were female. This allowed nuclear
material from the male donor cells to be traced within the
recipient using the male Y chromosome.
Myeloablative BMT can be associated with significant
morbidity.25 All transplanted mice were therefore left to recover
for 6 weeks prior to any further experimentation. For the total
duration of the experiment, 2 mice within the BMT control
group were removed from the study due to transplant-related
complications. No complications were observed in the YG8R
mice. A single YG8R mouse assigned to the BMT YG8R group
was removed from the study due to illness (unrelated to its
genetic phenotype), before any experimental intervention, on
veterinary advice. BMT was shown to have statistically signifi-
cant (p< 0.05) negative effects on the weight of both YG8R
and control mice (data not shown).
PB Mononuclear Cell Counts
and Detection of Chimerism
At 6 and 20 weeks post-BMT, hematopoietic reconstitution was
evaluated in PB by flow cytometry (FACSCalibur; Becton
Dickinson, Franklin Lakes, NJ). Briefly, 100ml PB was har-
vested from the tail vein and suspended in phosphate-buffered
saline (PBS) pH7.4/ethylenediaminetetraacetic acid (2mg/ml).
Red cells were removed using red cell lysis buffer, and the
remaining nucleated cell population was resuspended in PBS/
3% fetal bovine serum, counted using a hemocytometer, and
examined for EGFP expression when excited at 488nm using
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flow cytometric analysis. PB harvested from a non-transplanted
C57BL/6 mouse was used as a reference control. Data were
evaluated using Becton Dickinson CellQuest software.
Cytokine Administration
Cytokines doses were based on standard regimens for G-CSF
mobilization of PB hematopoietic stem cells in mice.16,26 Mice
received subcutaneous injection of murine G-CSF and SCF
(PeproTech, Rocky Hill, NJ; both 200 mg/kg) in PBS once daily
for 5 consecutive days. Treatments were repeated monthly. PBS
alone was administered as a vehicle control.
Neurobehavioral Testing
Body weight, rotarod, grip strength, string test, beam-walk test,
open field, and gait analysis were recorded monthly between 3
and 9 months of age as previously described.16
Tissue Preparation (Histology)
Mice were anaesthetized by intraperitoneal injection of Euthatal
and perfused with PBS followed by 4% paraformaldehyde in
PBS. The brains, spinal cords, and DRG were dissected, placed
in 4% paraformaldehyde in PBS for 24 hours at 48C, proc-
essed, and subsequently embedded in paraffin for sectioning on
a rotary microtome (LM2135; Leica Microsystems, Wetzlar,
Germany) and mounting on glass slides.
Immunohistochemistry and Imaging
Immunofluorescent labeling and microscopic imaging has been
described previously.16 Primary antibodies used were ßIII-
tubulin (ab78078, 1:250; Abcam, Cambridge, MA), calbindin-
D28K (C2724, 1:500; Sigma-Aldrich, St Louis, MO), CD11b/
c (ab1211, 1:100, Abcam), EGFP (ab6556, 1:500, Abcam),
glial fibrillary acidic protein (GFAP; ab33922, 1:200, Abcam),
IBA-1 (ab5076, 1:200, Abcam), NeuN (ab177487, 1:500 and
ab104224, 1:500, Abcam), S100 (MAB079, 1:200; Millipore,
Billerica, MA), S100 (Z0311, 1:200; Dako, Carpinteria, CA).
Secondary antibodies were Alexa Fluor 488/555, goat/donkey anti-
mouse (1:500), Alexa Fluor 488/555, goat/donkey anti-rabbit
FIGURE 1: Myeloablative allogeneic bone marrow (BM)
transplantation (BMT) and BM chimerism in YG8R mice. (A)
Experimental protocol using wild-type (WT) and YG8R mice
to investigate the effects of allogeneic BMT. At 3 months of
age, mice were assessed using an extensive range of behav-
ioral performance tests and subsequently given a BMT from
a ubiquitously expressing enhanced green fluorescent pro-
tein (EGFP) donor. After 8 weeks, mice were again assessed
at monthly time points using behavioral performance tests.
A subset of transplanted YG8R mice were also given
monthly infusions of granulocyte-colony stimulating factor
(G-CSF) and stem cell factor (SCF; red arrows). At 9 months
of age, mice were euthanized for histological analysis. (B)
Three-month-old recipient mice were given an allogeneic
BMT to create EGFP-expressing BM chimeras. Mice were
lethally irradiated, with a single dose of 1,000rad, 6 hours
prior to receiving 13107 unfractionated BM EGFP-
expressing cells by tail vein injection. (C) Flow cytometric
analysis (histogram) to determine the level of BM chimerism
within EGFP BM cell–transplanted mice 6 weeks post-trans-
plant. The percentage of peripheral blood (PB) mononuclear
cells (MNCs), harvested from transplanted mice, that were
positive for EGFP was calculated (MNCs with a relative fluo-
rescence higher than that of cells derived from non-trans-
planted WT control mice [white peak]). (D) The PB MNC
counts of both non-transplanted and transplanted WT con-
trol and YG8R mice. Statistical comparisons of control ver-
sus YG8R, YG8R versus BMT YG8R, and control versus BMT
control mice were analyzed using analysis of variance fol-
lowed by Holm–Sidak multiple comparisons test.
***p<0.001. Values represent mean6 standard error of the
mean. For all tests, n54 (BMT YG8R), all other groups
n55.
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(1:500), and Alexa Fluor 488/555, donkey anti-goat (1:500;
Invitrogen, Carlsbad, CA). Sections were mounted in VECTA-
SHIELD medium containing the nuclear dye 40,60-diamidino-2-
phenylindole (Vector Laboratories, Burlingame, CA).
Fluorescent In Situ Hybridization
Sections (8 mm) were processed and labeled as previously
described.27 Fluorescent in situ hybridization (FISH) probes
(mouse: chromosomes X [locus: Xqc3, green 5-fluorescein 20-
deoxyuridine 50-triphosphate (dUTP)] and Y control probe
[locus: Y, red 5-ROX dUTP]; Empire Genomics, Buffalo, NY)
were applied directly to the tissue sections. DNA was denatured
at 838C for 5 minutes and then renatured with FISH probes by
incubating overnight at 378C.
Using epifluorescence microscopy, each section was
scanned for Purkinje cell or DRG neurons containing the Y
chromosome. Each cell was subsequently scanned using
confocal microscopy acquiring 0.1- to 0.2 mm serial sections
throughout the entire cell soma. All Z-stack and 3-dimensional
imaging was created using both Leica Application Suite
Advanced Fluorescence software and Volocity 3D image soft-
ware (PerkinElmer, Waltham, MA).
Histological Staining
For histological assessment, tissues were sectioned, deparaffi-
nated, rehydrated, and stained with hematoxylin and eosin
(visualization of DRG vacuoles).
Cell Quantification/Measurements
Cell numbers, DRG vacuole quantification, and neuronal cell
size measurements were recorded as previously described.16
Binucleate Cells
Fusion of BM-derived cells with other cell types reveals the for-
mation of binucleate heterokaryons; thus, identification of
binucleate cells in the nervous system can be used as an indirect
measure of these cell fusion events.28 Each section was scanned
along either the entire length of the Purkinje cell layer or the
cross-sectional area of the DRG/cerebellar dentate nucleus, for
neuronal cell bodies containing 2 separate nuclei. A minimum
of 1,000 DRG neurons, 1,000 Purkinje neurons, or 500 cere-
bellar dentate nucleus neurons from each mouse were
examined.
Protein Analysis
Proteins were isolated from microdissected formalin-fixed, par-
affin-embedded (FFPE) cerebellum sections using the Qpro-
teome FFPE Tissue kit (Qiagen, Valencia, CA) according to the
manufacturers’ instructions. Subsequent Western blotting of
protein lysates and densitometric analysis were carried out as
previously described.29 Primary antibodies used were anti-b
actin (ab8227, 1:5,000, Abcam), anti-catalase (C0979, 1:2,000,
Sigma-Aldrich), anti-human frataxin (ab110328, 1:2,000,
Abcam), anti-frataxin (ab113691, 1:2,000, Abcam), anti–gluta-
thione peroxidase-1 (ab22604, 1:1,000, Abcam), anti-NeuN
(ab177487, 1:5,000, Abcam), anti–nuclear factor (erythroid-
derived 2)-like 2 (Nrf2; sc-722, 1:3,000; Santa Cruz
Biotechnology, Santa Cruz, CA), anti-peroxisome proliferator-
activated receptor gamma coactivator 1-alpha (PGC-1alpha)
(sc-13067, 1:3,000, Santa Cruz Biotechnology), anti-SOD1
(ab16831, 1:5,000, Abcam), and anti-SOD2 (ab16956,
1:5,000, Abcam). (Of note, increases in total frataxin are likely
to be underestimated when compared to human frataxin due to
differences in antibody (ab113691, Abcam) species reactivity;
the human protein reactivity of the antibody is approximately
50% of mouse protein reactivity at the same concentration.
Commercial mouse-specific frataxin antibodies are not
available.)
Statistical Analysis
Those analyses that did not employ longitudinal replicates from
the same animal were performed using Prism (GraphPad, La
Jolla, CA). Where data were known or predicted to violate
assumptions for parametric statistical testing (not sampled from
populations that follow a Gaussian distribution and/or unequal
variances between groups), an equivalent non-parametric test
was performed. Data between 2 groups were analyzed using
either the unpaired t test or Mann–Whitney U test with appro-
priate correction for multiple comparisons using the Holm–
Sidak and Bonferroni methods, respectively. Statistical compari-
sons for> 2 groups were analyzed using either analysis of vari-
ance followed by Holm–Sidak multiple comparison test or
Kruskal–Wallis followed by Dunn’s multiple comparison test
between groups. Histological analyses of spinal cord regions of
interest were analyzed separately in light of known pathophysi-
ology of disease. For longitudinal analyses, multiple regression
with cluster analysis and robust standard errors (Stata v12; Sta-
taCorp, College Station, TX) was used to assess the effect of
the test variable while taking into account the effect of other
variables including disease model (YG8R), BMT, and age as
well as correlation between longitudinal replicates from the
same individual. For all tests, values of p< 0.05 were consid-
ered statistically significant. Statistical tests were all 2-sided.
Data are represented as mean6 standard error of the mean
(SEM).
Results
To investigate the therapeutic effects of BMT, we used 3-
month YG8R transgenic mice. These mice are frataxin-
deficient and develop progressive neurodegeneration and
cardiac pathology.16,21,30
Detection of EGFP-BM Chimerism and
Mobilization of PB Mononuclear Cells
in Mice with FA
We successfully established chimeric (wild-type control or
YG8R) mice stably reconstituted with EGFP-expressing
BM cells containing wild-type copies of the Fxn gene
(see Fig 1). At 6 weeks post-transplantation, approxi-
mately 95% of nucleated cells within the PB of trans-
planted mice were EGFP-positive and thus donor-
derived. No significant change in the levels of EGFP-
ANNALS of Neurology
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positive cells in the PB were observed at 20-weeks post-
transplant (data not shown). More than double the num-
ber of circulating mononuclear cells (MNCs) were
present in PB of transplanted compared to non-trans-
planted YG8R mice. By contrast, BMT in wild-type con-
trols did not result in an increased circulating MNC
number when compared to age-matched non-trans-
planted controls.
BMT of Cells That Stably Express Wild-Type
Fxn Improves Neurobehavioral Deficits
Motor coordination and locomotor activity in both trans-
planted and non-transplanted mice was assessed monthly
for 6 months. At 3 months of age (before therapeutic
intervention) and throughout the duration of the study,
neurological deficits were apparent in the non-trans-
planted YG8R mice compared to age-matched non-trans-
planted wild-type controls (Fig 2).
BM-transplanted YG8R mice showed significant
improvements in grip strength tests, beam walk tests,
open field tests (middle square), and gait analyses, com-
pared to untreated YG8R mice (see Fig 2). No overall
improvements were seen in either the rotarod or string
test. Transplant had a negative effect on open field (total
squares) performance. BMT in wild-type control mice
resulted in no improvements in performance when
FIGURE 2: Improvements in neurobehavioral deficits in YG8R mice after allogeneic bone marrow transplantation (BMT). (A–E)
Longitudinal results for (A–D) motor performance and locomotor performance (E; open field test) in mice from 3 to 9 months
of age. (F) Footprint (gait) analysis and (G) representative footprint traces in mice 9 months of age. For A–E, statistical analysis
employed a regression model to determine whether there was an independent significant effect of disease model (YG8R) or
BMT on behavioral score. Three-month comparisons (pre-transplant; control vs YG8R; A–E) were analyzed using the unpaired t
test, with the exception of open field (middle square), where the Mann–Whitney U test was employed. Statistical comparisons
of control versus YG8R, YG8R versus BMT YG8R, and control versus BMT control for footprint analysis (F) were compared
using analysis of variance followed by Holm–Sidak multiple comparisons test. *p<0.05, **p<0.01, ***p<0.001, ns5not signifi-
cant; values represent mean6 standard error of the mean. For all tests, n54 (BMT YG8R), all other groups n55.
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compared to age-matched non-transplanted wild-type
controls, with the exception of a small but significant
improvement in the beam walk test. Conversely, some
decline in performance was also evident in the open field
(total squares) and gait analysis. As a deterioration in
locomotor performance using the open field test (total
squares) was observed in both transplanted YG8R and
control mice, it is likely this effect was caused by high-




Using immunoblotting techniques, we measured protein
levels of both endogenous human frataxin (expressed by
the humanized YG8R mouse) and total frataxin (mouse
frataxin [wild-type transplant-derived frataxin]1 human
frataxin) in the cerebellum of YG8R mice (aged 9
months). Frataxin protein levels were calculated by nor-
malizing to levels of internal reference proteins b-actin
and NeuN detected on the same blot. BMT in YG8R
mice resulted in a marked increase in total frataxin
expression; human frataxin expression was elevated, but
not significantly. Notably, in all cases, increases in fra-
taxin expression were more prominent when normalized
to the neuronal-specific marker NeuN than when nor-
malized to ubiquitously expressed b-actin, suggesting that
BMT, at least in part, potentiates increases in neuronal
frataxin (Table).
Frataxin deficiency results in dysregulation in cellular
antioxidant defenses,32 with deficiencies in key antioxidant
regulators including PGC-1alpha and Nrf2.33,34 BMT in
YG8R mice was associated with significant increases in
PGC-1alpha expression. No significant increases in the
expression of the antioxidants SOD1, SOD2, catalase, and
glutathione peroxidase-1 were apparent (see Table).
BMT Reverses FA-Associated Pathology
YG8R mice showed vacuolar degeneration of large sen-
sory DRG neurons, loss of neurons within the dorsal
nucleus of Clarke (DNoC), and degeneration of neurons
of the cerebellar dentate nucleus, associated with astro-
gliosis and microglial infiltration (Figs 3 and 4), all
changes that closely mimic those of human FA.3,5
BMT in YG8R mice completely attenuated intracellular
TABLE. BMT Elevates Both Frataxin Levels and Antioxidant Defenses in YG8R Mice
Protein Normalized to YG8R BMT YG8R
FA-associated proteins
Human frataxin ß-actin 1.006 0.120 1.2246 0.136
NeuN 1.006 0.147 1.6186 0.279
Total frataxin ß-actin 1.006 0.066 1.4866 0.182
NeuN 1.006 0.074 1.8826 0.263a
Antioxidant regulators
PGC1alpha NeuN 1.006 0.157 2.0986 0.409a
Nrf2 NeuN 1.006 0.151 1.6956 0.333
Antioxidant enzymes
SOD1 NeuN 1.006 0.092 1.9566 0.430
SOD2 NeuN 1.006 0.144 1.3856 0.227
Catalase NeuN 1.006 0.082 1.7636 0.366
GPX1 NeuN 1.006 0.047 2.1446 0.581
The relative protein expression levels of human frataxin, total frataxin, PGC1alpha, Nrf2, and antioxidant enzymes (SOD1, SOD2, catalase, and
glutathione peroxidase 1 [GPX1]) within the cerebellum of YG8R mice. Statistical comparisons between YG8R and BMT YG8R were analyzed
using (human frataxin, antioxidant regulators) unpaired t tests with correction for multiple comparisons using the Holm–Sidak method; or (total
frataxin, antioxidant enzymes) Mann–Whitney U tests with correction for multiple comparisons using the Bonferroni method. For all tests, n5 4
(BMT YG8R), n5 5 (YG8R).
ap< 0.05, values represent means6 standard error of the mean (expressed relative to YG8R).
BMT5 bone marrow transplantation; FA5 Friedreich’s ataxia.
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(nuclear and cytoplasmic) vacuolar degeneration of the
large sensory neuronal cell bodies, and this change was
associated with a reduced satellite cell-to-DRG neuron
ratio, a likely consequence of improved large sensory
neuronal cell survival (see Fig 3).3 Within the cerebellar
dentate nucleus, mean neuronal size was increased, indi-
cating preservation of large neuronal cells. Alternatively,
we found no significant preservation of neurons in spinal
cord DNoC of transplanted mice.
BMT in YG8R mice resulted in reduced numbers
of GFAP-positive astrocytes in the spinal cord (see Fig
4). CD11b/c-positive macrophages/microglial cells in
both the spinal cord and cerebellar dentate nucleus were
increased in transplanted YG8R mice. BMT in wild-type
controls resulted in elevated GFAP and CD11b/c cell
numbers in the cerebellar dentate nucleus and the spinal
cord lateral corticospinal tract, respectively, when com-
pared to age-matched non-transplanted controls.
FIGURE 3: Bone marrow transplantation (BMT) reverses Friedreich’s ataxia–associated pathology. (A) High-powered image of
hematoxylin and eosin (H&E)-stained dorsal root ganglion (DRG) neurons containing vacuoles (arrows). (B) DRG depicting
reductions in vacuolization of the large sensory neurons within transplanted YG8R mice. (C) The frequency of DRG neurons
containing nuclear or cytoplasmic vacuoles. (D) Typical DRG histology with satellite glial cells (green) covering the surface of
DRG sensory neurons (red). (E) The DRG satellite-to-neuron cell ratio. (F, G) The size range (F) and mean cell size (diameter; G)
of DRG neurons. (H) High-powered images of ßIII-tubulin–labeled neurons within the cerebellar dentate nucleus (DN). (I, J) The
size range (I) and mean cell size (diameter; J) of cerebellar DN neurons. (K, L) Representative low-powered (K) and high-
powered (L) images of NeuN-positive neurons within the dorsal nucleus of Clarke (DNoC). (M) The number of DNoC neurons/
mm2. All statistical comparisons of control versus YG8R, YG8R versus BMT YG8R, and control versus BMT control mice were
analyzed using analysis of variance followed by Holm–Sidak multiple comparisons test. *p<0.05, **p<0.01, ***p<0.001; values
represent mean6 standard error of the mean. For all tests, n54 (BMT YG8R), all other groups n55. DAPI540,60-diamidino-2-
phenylindole; DC5dorsal column; EGFP5enhanced green fluorescent protein.
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FIGURE 4: Bone marrow transplantation (BMT) alters glial/immune cell infiltration to areas of tissue injury. (A, C) The number
of glial fibrillary acidic protein (GFAP)-positive (A) and CD11b/c-positive (C) cells/mm2 within the spinal cord or cerebellar den-
tate nucleus. (B, D) Images of GFAP-positive (B) and CD11b/c-positive (D) cells within the cerebellar dentate nucleus or spinal
cord. Statistical comparisons of control versus YG8R, YG8R versus BMT YG8R, and control versus BMT control mice were ana-
lyzed using analysis of variance followed by Holm–Sidak multiple comparisons test (A [spinal cord], C) or Kruskal–Wallis fol-
lowed by Dunn’s multiple comparison test (A [dentate nucleus]). *p<0.05, **p<0.01, ***p<0.001; values represent
means6 standard error of the mean. For all tests, n54 (BMT YG8R), all other groups n55. ACST5 anterior corticospinal tract;
DAPI540,60-diamidino-2-phenylindole; DC5dorsal column; DNoC5dorsal nucleus of Clarke; EGFP5enhanced green fluores-
cent protein; LCST5 lateral corticospinal tract; SCT5 spinocerebellar tract.
ANNALS of Neurology
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Large Numbers of BM-Derived Cells Infiltrate
the Nervous System of YG8R Mice after BMT
We detected significant numbers of EGFP-positive cells
within DRG, peripheral nerves, spinal cord, and cerebel-
lum of YG8R mice transplanted with EGFP-expressing
BM cells (Fig 5). The frequency of EGFP-expressing cells
was significantly higher within the spinal cord and cere-
bellar dentate nucleus of transplanted YG8R mice com-
pared to transplanted wild-type controls. CD11b/c–
positive or IBA-1–positive macrophages/microglia were,
as expected (being of myeloid origin), found to co-
express EGFP in both wild-type and YG8R transplanted
mice (see Figs 4D and 5C). EGFP-positive cells did not
co-express the astrocytic marker GFAP in spinal cord or
cerebellum (see Fig 4B). However, significant numbers of
cells expressed the satellite/Schwann cell marker S100
within the DRG and peripheral nerves, respectively (see
Fig 5). The morphological characteristics of these cells
matched those of typical S100 cells in situ within their
given anatomical locations. The frequency of EGFP-
positive cells surrounding the DRG neurons was the
same in transplanted YG8R and age-matched trans-
planted control mice.
Fusion of BM-Derived Cells within the Nervous
System of YG8R Mice
We found EGFP-expressing BM-derived cells integrated
with DRG neurons to form binucleate NeuN-positive
cells (Fig 6). The frequency of these binucleate DRG
neurons was significantly higher in transplanted YG8R
mice than in non-transplanted YG8R mice. We also
found EGFP-positive cells within the cerebellum of the
YG8R mouse associated with typical binucleate Purkinje
cell heterokaryons. EGFP-positive cells, with typical neu-
ronal morphology, expressing both the neuronal markers
NeuN and ßIII-tubulin, were identified (albeit very
rarely) within the cerebellar dentate nucleus. A propor-
tion of these cells were also binucleate.
Evidence for Fusion and Genetic Integration
between Wild-Type BM-Derived Cells and
Endogenous Neurons in YG8R Mice
Utilizing sex-mismatched BMT (transplanting male
donor wild-type BM cells into female YG8R mice; see
Fig 1B), the presence of male BM-derived cells and/or
nuclei in the female YG8R brain was detected using in
situ hybridization with fluorescently labeled X and Y
chromosomal DNA probes (see Fig 6). Cerebellar and
DRG sections were selected for examination, and Pur-
kinje cells or DRG neurons, respectively, were analyzed
for their sex chromosome content. Using laser scanning
confocal microscopy, the Y chromosome was readily
detected scattered throughout the tissue. In a number of
Purkinje cells and DRG neurons, identified by their
unique morphology and location, a Y chromosome was
detected within the nucleus (nuclei did not always con-
tain 2 sex chromosomes due to the thickness of the sec-
tions [8mm] encompassing less than half of the entire
cell soma). Furthermore, several Purkinje cells and DRG
neurons were shown to contain 3 or 4 distinct chromo-
somes (XXY or XXXY), providing evidence for fusion
and donation of nuclear genetic material between male
wild-type BM-derived cells and female YG8R host
neurons.
G-CSF and SCF Administration in Conjunction
with BMT Further Increases BM Cell Integration
into the Cerebellum and DRG of YG8R Mice
A subgroup of transplanted YG8R mice were subcutane-
ously injected with the cytokines G-CSF and SCF daily
for 5 consecutive days, each month for 5 consecutive
months (see Fig 1A). Cytokine administration stimulated
mobilization of MNCs approximately 3-fold in
transplanted YG8R mice (3.356 0.293 107 cells/ml
[BMT YG8R] vs 8.716 0.113 107 cells/ml [BMT YG8R
G-CSF/SCF], mean6 SEM, n5 4 and n5 5, respec-
tively, p< 0.001, unpaired t test). G-CSF/SCF administra-
tion in transplanted mice also led to significant
improvements in all motor coordination and locomotor
activity tests when compared to non-transplanted YG8R
mice (including the rotarod, string test and open field test
[Fig 7A–C], where no initial improvements in perfor-
mance were evident when YG8R mice received a trans-
plant alone [see Fig 2]). Only in the open field test (total
squares) and gait analysis did G-CSF/SCF administration
in transplanted mice lead to a significant improvement in
performance over YG8R mice that had received a trans-
plant alone (see Figs 7B and 7C).
G-CSF/SCF administration increased frequencies of
EGFP-positive cells within DRG and dorsal spinal roots,
but decreased frequencies within the spinal cord DNoC
and dentate nucleus (see Fig 7). Furthermore, it led to
an increased frequency in both EGFP-expressing cells
surrounding DRG neurons and binucleate Purkinje cells
(3-fold) within the cerebellum. No changes in the fre-
quency of GFAP-expressing cells were observed with the
addition of G-CSF/SCF (data not shown); however,
CD11b/c macrophages/microglia numbers were signifi-
cantly reduced in number within both the spinal cord
and dentate nucleus. We also found a significant preser-
vation of neurons in spinal cord DNoC of transplanted
mice that had received G-CSF/SCF. Of note, G-CSF/
SCF administration had no adverse effect on any out-
come analyzed within this study.
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FIGURE 5: Bone marrow transplantation (BMT) results in large numbers of enhanced green fluorescent protein (EGFP)-express-
ing bone marrow–derived cells migrating and integrating into the nervous system. (A, B) The frequency (A) and representative
images (B) of EGFP-positive cells within the nervous system of transplanted mice. (C) EGFP-expressing cells labeled with either
S100 or IBA-1 within dorsal root ganglia (DRG). The hatched areas depict the locations of the higher-powered images. (D) An
EGFP-expressing S100-positive Schwann cell wrapping around an axon. (E) The frequency of EGFP cells wrapping each DRG
neuron. All statistical comparisons of BMT control versus BMT YG8R were analyzed using the unpaired t test. Correction for
multiple comparisons within each anatomical location were made using the Holm–Sidak method. **p<0.01, ***p<0.001; values
represent mean6 standard error of the mean. For all tests, n54 (BMT YG8R), all other groups n55. ACST5 anterior cortico-
spinal tract; DAPI540,60-diamidino-2-phenylindole; DC5dorsal column; DNoC5dorsal nucleus of Clarke; LCST5 lateral corti-
cospinal tract; SCT5 spinocerebellar tract.
FIGURE 6: Bone marrow transplantation (BMT) results in enhanced green fluorescent protein (EGFP) bone marrow (BM)-derived
cells fusing with neurons throughout the nervous system of YG8R mice. (A) An EGFP-expressing binucleate dorsal root gan-
glion (DRG) neuron labeled with NeuN. The hatched areas in the smaller images depict the locations of the 2 distinct nuclei.
(B) A binucleate DRG neuron visualized using hematoxylin and eosin (H&E) staining. (D) An EGFP-expressing binucleate Pur-
kinje cell. (E) A binucleate Purkinje cell visualized using calbindin-D28K/40,60-diamidino-2-phenylindole (DAPI) labeling. (G) An
EGFP-expressing cell in the cerebellar dentate nucleus (DN). The smaller images depict the same cell coexpressing NeuN. (H)
ßIII-tubulin–expressing binucleate cells (arrows) within the cerebellar DN. (C, F, I) The percentage of binucleate DRG neurons
(C), Purkinje cells (F), and cerebellar DN neurons (I) in non-transplanted and transplanted mice. (J, K) Fluorescent in situ hybridi-
zation (FISH) analysis in BMT YG8R mice, using fluorescently labeled X (green) and Y (red) chromosomal probes, shows the
presence of the male donor Y chromosome in the nucleus of both Purkinje cells (J) and DRG neurons (K). (L, M) Purkinje cell (L)
and DRG neuron (M) heterokaryons in BMT YG8R mice containing 3 distinct chromosomes (XXY), providing evidence for fusion
between male wild-type BM-derived cells and female YG8R host neurons. Hatched areas indicate the locations of the higher-
powered images without DAPI labeling. Statistical comparisons of control versus YG8R, YG8R versus BMT YG8R, and control
versus BMT control mice were analyzed using analysis of variance followed by Holm–Sidak multiple comparisons test (C, F) or
Kruskal–Wallis followed by Dunn’s multiple comparison test (I). *p<0.05; values represent mean6 standard error of the mean.
For all tests, n54 (BMT YG8R), all other groups n55.
FIGURE 7: Granulocyte-colony stimulating factor (G-CSF) and stem cell factor (SCF) administration improves behavioral and
anatomic parameters in YG8R mice that have received a bone marrow transplant (BMT). (A, B) Longitudinal results for (A)
motor performance (rotarod and string test; A) and locomotor performance (open field test: total squares; B) in mice from 3 to
9 months of age. (C) Footprint (gait) analysis in mice 9 months of age. (D–G) The number of enhanced green fluorescent pro-
tein (EGFP) cells/mm2 within the nervous system (D), the frequency of EGFP cells wrapping each dorsal root ganglion (DRG)
neuron (E), the percentage of binucleate Purkinje cells (F), and the number of CD11b/c-positive cells/mm2 within the spinal
cord and dentate nucleus (G). (H) The number of dorsal nucleus of Clarke (DNoC) neurons/mm2. Statistical comparisons of
YG8R versus BMT YG8R G-CSF/SCF and BMT YG8R versus BMT YG8R G-CSF/SCF were analyzed using multiple linear regres-
sion (A, B), unpaired t test (correction for multiple comparisons within each anatomical location were made using the Holm–
Sidak method; D, E, F), or an analysis of variance followed by Holm–Sidak multiple comparisons test (C, G, H). Multiple regres-
sion was employed to determine whether there was an independent significant effect of cytokine administration (in trans-
planted YG8R mice) or BMT1 cytokine administration (in YG8R mice) on behavioral score. *p<0.05, **p<0.01, ***p<0.001;
values represent mean6 standard error of the mean. For all tests, n54 (BMT YG8R), all other groups n55. ACST5 anterior
corticospinal tract; DC5dorsal column; LCST5 lateral corticospinal tract; ns5not significant; SCT5 spinocerebellar tract.
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Discussion
Here we provide evidence that transplantation of BM
cells expressing normal copies of the frataxin gene (Fxn)
in a humanized mouse model of FA leads to significant
functional, biochemical, and pathological improvements.
Tissue repair is thought to involve the selective recruit-
ment of stem and progenitor cells, both local and including
those derived from the BM.35,36 Post-BMT, YG8R mice
displayed a disease-related mobilization of endogenous
MNCs from the BM niche into the PB. Transplanted con-
trol mice showed no signs of elevated circulating MNCs,
providing possible insights into how "healthy" BM-derived
cells respond in non-pathological/pathological conditions.
Impaired mobilization of progenitor cells may be inherent
to the disease37; in support of this, we have previously
reported a deficiency in neural precursors found throughout
the nervous system of YG8R mice.16
EGFP-expressing BM cells expressed wild-type fra-
taxin, and neurological improvements may relate to the
elevated levels of frataxin within the nervous system. Our
protein expression and histological studies support an
increase in neuronal frataxin levels post-transplant. BMT
also increased expression of PGC-1alpha, a key regulator
of cellular redox homeostasis associated with frataxin
deficiency.38 Re-establishing normal cellular function
through increasing frataxin levels holds therapeutic prom-
ise. This has been demonstrated experimentally using
gene therapy approaches, where increasing cellular fra-
taxin levels through viral delivery of a FXN transgene led
to robust correction of cellular parameters in models of
FA,39,40 in both cell culture and myocardial tissue.
BMT in YG8R mice resulted in stable long-term
engraftment of EGFP-positive BM cells with extensive
integration of EGFP-expressing BM-derived cells into
areas of FA-associated nervous tissue injury, namely
DRG, the spinal cord, and cerebellum.41 Studies have
previously reported that intrathecally injected in vitro
culture-expanded mesenchymal stem cells (MSCs) can
migrate into the DRG of FA mice and exert a neurotro-
phic effect.42 During BMT, small numbers of donor
MSCs are co-infused with injection of BM MNCs; how-
ever, they do not replace recipient MSCs despite com-
plete engraftment of the donor wild-type hematopoietic
system.43 This lack of MSC engraftment post-BMT
implies that it is unlikely donor-derived wild-type MSCs
afford the therapeutic effects of BMT in YG8R mice.
In our study, EGFP-positive cells expressed NeuN
and S100 within the dorsal spinal root and/or DRG,
indicating that BM-derived cells contribute genetic mate-
rial to neuronal, satellite cell, and myelinating Schwann
cell populations. Both dysfunctional frataxin-deficient
neurons and glia are likely to contribute to neuropathol-
ogy in FA.6,7 Pathology in FA occurs primarily in the
DRG, with significant but independent changes to both
the large sensory neurons and surrounding satellite cells,
ultimately resulting in neuronal atrophy.5 Replacement of
these dysfunctional cell types within the DRG of trans-
planted mice, which under normal conditions provide
bidirectional trophic support to one another,5 may
improve the survival of DRG neurons. EGFP-positive
cells surrounding the DRG neurons also expressed the
macrophage marker IBA-1. Following nerve damage,
neuron–macrophage interactions can result in the acqui-
sition of a pro-regenerative phenotype in macrophages,
potentially enhancing the axonal regenerative capacity.44
There are also reports that BM-derived macrophages can
become satellite-like cells following nerve injury, envelop-
ing DRG neurons and modifying the neuronal environ-
ment through regulation of neurotrophin synthesis.45
BM-derived cells fusing with neurons following
BMT, to form binucleate heterokaryons, has been
observed in humans.9 Moreover, pathophysiological pro-
cesses associated with neurological injury in FA appear to
augment these fusion events.46 Experimentally, in mice
that have received BMT, BM-derived cells fuse with cere-
bellar Purkinje cells to form stable heterokaryons.47
Observations from these studies have suggested that BM
cells fusing with neurons and donating their genetic
material represent a biological cell-mediated mechanism
for neuronal protection in the adult brain. EGFP-
expressing binucleate heterokaryons within both the cere-
bellum (cerebellar dentate nucleus neurons and Purkinje
cells) and DRG of YG8R mice revealed significant
nuclear integration of transplanted cells into nervous sys-
tem tissue. Moreover, sex-mismatched BMT (transplant-
ing male donor BM cells into female YG8R mice) and
detection of the Y chromosome provided definitive evi-
dence for cell fusion and donation of nuclear material
between donor BM-derived cells and host YG8R neu-
rons. Cellular fusion has previously been noted in cere-
bellar Purkinje cells47 and spinal cord motor neurons.48
The novel identification of EGFP-expressing binucleate
DRG and cerebellar dentate nucleus neurons, in addition
to sex chromosome analysis, widens the range of cell
types in which fusion has been reported. We also show
that BMT alone increased the frequency of cell fusion
within the DRG. Each fused binucleate cell within trans-
planted mice, in theory, contains a corrected form of the
Fxn gene. Genes derived from the wild-type–donated
nucleus are clearly present and expressed within the
YG8R host cell, demonstrated through translation of the
EGFP transgene, providing novel proof of concept of
BMT gene therapy within the nervous system. In organs
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other than the brain, such as the liver, BM cell migra-
tion and integration represent an important process by
which degenerating genetically damaged cells can be
rescued.14,15
We recently demonstrated that the BM stem cell–
mobilizing cytokines G-CSF and SCF display strong neu-
roprotective effects in the YG8R mouse model (without
prior BMT).16 Here, we show that the combination of
G-CSF and SCF not only displays direct neuroprotective
effects in FA,16 but also aids the delivery of BM cells to
sites of FA-associated injury, stimulating neural repair.
Significantly, we show also that the administration of
G-CSF/SCF to transplanted YG8R mice further mediates
improvements in motor coordination, locomotor activity,
and FA-related pathology. In response to G-CSF/SCF
administration, the incidence of both Purkinje cell fusion
and EGFP-expressing DRG satellite-like cells/macrophages
was elevated. Induced migration of BM-derived cells into
the CNS through G-CSF/SCF exposure is likely due to
the biological action of these drugs on the brain microen-
vironment, or the cells, and not completely dependent on
CNS injury or inflammation.19,20 Cytokine administration
displayed significant anti-inflammatory properties in both
the spinal cord and dentate nucleus of transplanted YG8R
mice, which likely also explains reductions in EGFP-
positive cells detected within those anatomical areas after
cytokine treatment. Whether BM integration is enhanced
through cytokines simply boosting the levels/availability of
circulating stem cells, or they have direct effects on migra-
tory cell signaling processes or passage of cells through the
blood–brain barrier, is unknown; these hypotheses warrant
further investigation.
Currently, there are no effective treatments to slow
the progression of FA. Our findings demonstrate the feasi-
bility of allogeneic BMT as a potential "gene replacement"
therapy that may reduce or help reverse neurological dis-
ability in patients with FA. This procedure has been exten-
sively studied in humans for other diseases, and it must be
taken into consideration that, when used clinically, alloge-
neic transplantation carries significant risks of morbidity
and mortality. The use of reduced-intensity and/or
reduced-toxicity conditioning could be considered to miti-
gate tissue injury and potential long-term side effects asso-
ciated with high-dose myeloablative conditioning. In
conclusion, we have shown that allogeneic BMT offers the
prospect of a novel, rapidly translatable, disease-modifying,
and neuroregenerative treatment for FA.
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